This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Diseases of white blood cells
  • /
  • Management of febrile neutropaenia: ESMO Clinical ...

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines

Read time: 1 mins
Last updated:31st Aug 2016
Management of Febrile Neutropaenia: ESMO Clinical Practice Guidelines - European Society For Medical Oncology (ESMO)

Febrile neutropaenia is the development of fever, often with other signs of infection, in a patient with neutropaenia, an abnormally low number of neutrophil granulocytes in the blood. Despite major advances in prevention and treatment, febrile neutropaenia is associated with the intensity of chemotherapy and remains one of the most frequent and serious complications of cancer chemotherapy. The updated ESMO Clinical Practice Guidelines include key recommendations for the assessment, risk assessment and management of febrile neutropaenia including patient education and local policies.


Read full guideline